"At Acuity Pharmaceuticals we faced many challenges back in 2003. Five years later, we can view our scientific and financial successes with the benefit of hindsight to seek the contributing factors to that success. BioAdvance was one of the first companies we presented our company to. We received quick feedback and then were involved in a thorough diligence process which gave us more input and encouragement. At that early juncture, BioAdvance decided to invest, yet it was far more than money that made the difference. The BioAdvance team provided contacts and an effective sounding board for our development during those formative years."
Dale Pfost
Former CEO
Acuity Pharmaceuticals
Philadelphia, PA
Dale Pfost
Former CEO
Acuity Pharmaceuticals
Philadelphia, PA
Today’s Top Regional Life Sciences Stories from Business Wire
| New UV/Ozone Sanitizer for the Millions of Consumers with Oral Appliances |
| CONSHOCKEN, Pa.--(BUSINESS WIRE)--New UV/Ozone Sanitizer for the Millions of Consumers with Oral Appliances. NatureZone is a safe and effective way to disinfect, sanitize, and deodorize all common, removable oral appliances. |
| Hospitals, Healthcare Providers to Benefit from New Premier Agreements for Reposable Surgical Instruments |
| CHARLOTTE, N.C.--(BUSINESS WIRE)--Premier Purchasing Partners, LP, today announced new agreements for reposable surgical instruments have been awarded to ConMed Corporation of Utica, N.Y.; Genicon Inc. of Winter Park, Fla.; Microline Surgical Inc. of Beverly, Mass.; and Surgical Innovations U.S., LLC of Virginia Beach, Va. Effective April 1, 2010, the agreements are available to acute care and continuum of care members of the Premier healthcare alliance. About Premier Inc., 2006 Malcolm Baldrige |
| CORRECTING and REPLACING Columbia Laboratories Reports Fourth Quarter and Year End 2009 Financial Results |
| LIVINGSTON, N.J.--(BUSINESS WIRE)--In the table entitled "CONDENSED CONSOLIDATED BALANCE SHEETS," the figure for "Accumulated deficit" under December 31, 2009 should read: (256,979,263) (sted (56,979,263)). The corrected release reads: COLUMBIA LABORATORIES REPORTS FOURTH QUARTER AND YEAR END 2009 FINANCIAL RESULTS Management will host Conference Call at 8:30 AM ET Today Columbia Laboratories, Inc. (Nasdaq: CBRX) today reported financial results of the three- and twelve-months periods ended Dece |
| Akorn, Inc. Enters into an Agreement to Sell Common Stock and Warrants |
| LAKE FOREST, Ill.--(BUSINESS WIRE)--Akorn, Inc. (NASDAQ: AKRX) a niche generic pharmaceutical company, announced today that it has entered into an agreement to issue and sell to Serum Institute of India Ltd. (“Serum”) 1,838,235 shares of the Company’s common stock at $1.36 per share or a 15% discount to the market closing price on March 5, 2010 of $1.60 per share, resulting in aggregate proceeds of $2,500,000. The Company also agreed to issue to Serum a warrant to purchase appr |
| Advaxis Develops Room Temperature Formulation of ADXS11-001 |
| NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--ADVAXIS DEVELOPS ROOM TEMPERATURE FORMULATION OF ADXS11-001 - Process Simplifies Immunotherapeutic’s Global Commercialization - long-term, room temperature, storage-stable form of its vaccines |
| SpineUniverse Launches Patient Case Collaboration Tool for Spine Surgeons |
| MONTCLAIR, N.J.--(BUSINESS WIRE)--SpineUniverse, a Vertical Health website, proudly introduces the Community Case Discussion for its network of spine professionals. This interactive forum allows spine specialists to engage with one another in the SpineUniverse Spinal Case Study Library. More than 6,000 spine surgeons—nearly 60% of all practicing spine surgeons in the United States—have joined SpineUniverse to market their practices, receive information on CME opportunities, and learn |
| PolyMedix Presents PMX-30063 Antibiotic Data at 8th World Congress on Trauma, Shock, Inflammation and Sepsis – TSIS 2010 |
| RADNOR, Pa.--(BUSINESS WIRE)--PolyMedix Presents PMX-30063 Antibiotic Data at 8th World Congress on Trauma, Shock, Inflammation and Sepsis – TSIS 2010 |
| Antares Pharma to Present at the 22nd Annual ROTH OC Growth Stock Conference |
| EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NYSE Amex: AIS) today announced that Paul K. Wotton, Ph.D., President and Chief Executive Officer, will present at the 22nd Annual Roth OC Growth Stock Conference on Wednesday, March 17, 2010 at 12:30 p.m. ET (Eastern Time). A live audio webcast of the presentation will be available at http://www.wsw.com/webcast/roth23/ais/. About Antares Pharma Antares Pharma is an emerging pharma that focuses on self-injection pharmaceutical products and tech |
| ACM Global Central Lab and BioClinica Discuss How Central Lab and EDC Providers Can Collaborate More Effectively in R&D Directions Webinar |
| ROCHESTER, N.Y. & NEWTON, Pa.--(BUSINESS WIRE)--ACM Global Central Laboratory and BioClinica are co-sponsoring the upcoming R&D Directions webinar on, “How Central Lab and Electronic Data Capture Providers Can Collaborate Effectively.” |
| Rex Medical Cleaner™ Rotational Thrombectomy System Receives 510(k) Clearance |
| CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Rex Medical, L.P., today announced that it has received 510(k) Clearance from the U.S. Food and Drug Administration (FDA) for the Cleaner™ Rotational Thrombectomy System. Cleaner™ technology is indicated for mechanical declotting of occluded native vessel dialysis fistulae and synthetic dialysis access grafts. Argon Medical Devices, Inc. will lead all marketing and distribution efforts for Cleaner™ in the United States, European Union and Can |
© Copyright 2008. BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania. All Rights Reserved.